BACKGROUND:Short-term aspirin therapy can lower the risk for venous thromboembolism (VTE) in high-risk patients, but whether the long-term use of low-dose aspirin reduces risk in healthy adults is uncertain. OBJECTIVE: To test the efficacy of long-term aspirin therapy for preventing VTE. DESIGN: Secondary analysis of a 10-year randomized, double-blind, placebo-controlled trial. SETTING:U.S. female health care professionals in the Women's Health Study. PARTICIPANTS: 39,876 initially healthy women age 45 years or older (26,779 gave blood samples that were evaluated for factor V Leiden, G20210A prothrombin, and MTHFR 677C>T polymorphisms). MEASUREMENTS: Documented VTE (deep venous thrombosis or pulmonary embolism) and unprovoked VTE (no recent surgery, trauma, or cancer diagnosis) were prospectively evaluated, secondary end points. INTERVENTION: Aspirin, 100 mg, or placebo on alternate days. RESULTS:Venous thromboembolism occurred in 482 women during follow-up, an incidence higher than that of myocardial infarction and nearly equal to that of stroke. The incidence of VTE (per 1000 person-years) was 1.18 among women randomly assigned to active aspirin, compared with 1.25 among women randomly assigned to placebo (relative hazard, 0.95 [95% CI, 0.79 to 1.13]; rate difference, -0.06 [CI, -0.28 to 0.16]). For unprovoked VTE, the relative hazard was 0.90 (CI, 0.70 to 1.16) and the rate difference was -0.06 (CI, -0.21 to 0.10). Relative hazards associated with aspirin use in higher-risk subgroups were 0.83 (CI, 0.50 to 1.39) among women with either factor V Leiden or the prothrombin mutation and 1.36 (CI, 0.77 to 2.41) among those with a history of VTE. LIMITATION: Venous thromboembolism was a secondary end point in the Women's Health Study. CONCLUSION: These data suggest that long-term, low-dose aspirin treatment has little effect on the prevention of VTE in initially healthy women. ClinicalTrials.gov registration number: NCT00000479.
RCT Entities:
BACKGROUND: Short-term aspirin therapy can lower the risk for venous thromboembolism (VTE) in high-risk patients, but whether the long-term use of low-dose aspirin reduces risk in healthy adults is uncertain. OBJECTIVE: To test the efficacy of long-term aspirin therapy for preventing VTE. DESIGN: Secondary analysis of a 10-year randomized, double-blind, placebo-controlled trial. SETTING: U.S. female health care professionals in the Women's Health Study. PARTICIPANTS: 39,876 initially healthy women age 45 years or older (26,779 gave blood samples that were evaluated for factor V Leiden, G20210A prothrombin, and MTHFR 677C>T polymorphisms). MEASUREMENTS: Documented VTE (deep venous thrombosis or pulmonary embolism) and unprovoked VTE (no recent surgery, trauma, or cancer diagnosis) were prospectively evaluated, secondary end points. INTERVENTION: Aspirin, 100 mg, or placebo on alternate days. RESULTS:Venous thromboembolism occurred in 482 women during follow-up, an incidence higher than that of myocardial infarction and nearly equal to that of stroke. The incidence of VTE (per 1000 person-years) was 1.18 among women randomly assigned to active aspirin, compared with 1.25 among women randomly assigned to placebo (relative hazard, 0.95 [95% CI, 0.79 to 1.13]; rate difference, -0.06 [CI, -0.28 to 0.16]). For unprovoked VTE, the relative hazard was 0.90 (CI, 0.70 to 1.16) and the rate difference was -0.06 (CI, -0.21 to 0.10). Relative hazards associated with aspirin use in higher-risk subgroups were 0.83 (CI, 0.50 to 1.39) among women with either factor V Leiden or the prothrombin mutation and 1.36 (CI, 0.77 to 2.41) among those with a history of VTE. LIMITATION: Venous thromboembolism was a secondary end point in the Women's Health Study. CONCLUSION: These data suggest that long-term, low-dose aspirin treatment has little effect on the prevention of VTE in initially healthy women. ClinicalTrials.gov registration number: NCT00000479.
Authors: Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija Journal: J Natl Compr Canc Netw Date: 2011-07-01 Impact factor: 11.908
Authors: Paolo Feltracco; Stefania Barbieri; Umberto Cillo; Giacomo Zanus; Marco Senzolo; Carlo Ori Journal: World J Gastroenterol Date: 2015-07-14 Impact factor: 5.742
Authors: Aaron S Kesselheim; Christopher T Robertson; Jessica A Myers; Susannah L Rose; Victoria Gillet; Kathryn M Ross; Robert J Glynn; Steven Joffe; Jerry Avorn Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: Tracy L Kinsey; Til Stürmer; Michele Jonsson Funk; Charles Poole; Ross J Simpson; Robert J Glynn Journal: Rheumatology (Oxford) Date: 2020-09-01 Impact factor: 7.580
Authors: Robert J Glynn; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Paul M Ridker Journal: N Engl J Med Date: 2009-03-29 Impact factor: 91.245